Stress Signal ULBP4, an NKG2D Ligand, Is Upregulated in Multiple Sclerosis and Shapes CD8+ T-Cell Behaviors
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received August 17, 2021
- Accepted in final form October 19, 2021
- First Published December 6, 2021.
Author Disclosures
- Ana Carmena Moratalla, MSc (anacarmena3{at}gmail.com),
- Yves Carpentier Solorio, BSc (yves.carpentier.solorio{at}umontreal.ca),
- Florent Lemaitre, MSc (grdflo.lemaitre{at}gmail.com),
- Negar Farzam-kia, BSc (negarf.16{at}gmail.com),
- Annie Levert, DEC (annie.levert2{at}hotmail.com),
- Stephanie E.J. Zandee, PhD (stephaniezandee{at}gmail.com),
- Boaz Lahav, BSc (boaz.lahav.chum{at}ssss.gouv.qc.ca),
- Jean Victor Guimond, MD (jeanvictorguimondjvg{at}gmail.com),
- Elie Haddad, MD, PhD (elie.haddad{at}umontreal.ca),
- Marc Girard, MD (m_girard{at}videotron.ca),
- Pierre Duquette, MD (pierre.duquette.1{at}umontreal.ca),
- Catherine Larochelle, MD, PhD (catherine.larochelle.med{at}ssss.gouv.qc.ca),
- Alexandre Prat, MD, PhD (a.prat{at}umontreal.ca) and
- Nathalie Arbour, PhD
- Ana Carmena Moratalla, MSc (anacarmena3{at}gmail.com),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Yves Carpentier Solorio, BSc (yves.carpentier.solorio{at}umontreal.ca),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Florent Lemaitre, MSc (grdflo.lemaitre{at}gmail.com),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Negar Farzam-kia, BSc (negarf.16{at}gmail.com),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Annie Levert, DEC (annie.levert2{at}hotmail.com),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Stephanie E.J. Zandee, PhD (stephaniezandee{at}gmail.com),
None
NONE
Funding organization(s): Canadian Institutes of Health Research
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Boaz Lahav, BSc (boaz.lahav.chum{at}ssss.gouv.qc.ca),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Jean Victor Guimond, MD (jeanvictorguimondjvg{at}gmail.com),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Elie Haddad, MD, PhD (elie.haddad{at}umontreal.ca),
Enzyvant Jasper Therapeutics Rocket Pharma
NONE
NONE
NONE
Invention of specific promoters
NONE
NONE
NONE
NONE
NONE
NONE
NONE
CIHR
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Marc Girard, MD (m_girard{at}videotron.ca),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Pierre Duquette, MD (pierre.duquette.1{at}umontreal.ca),
Member of advisory boards for Biogen-Idec, EMD Serono, Novartis, TEVANeuroscience, Genzyme.
NONE
NONE
NONE
Shared patent for a cellular adhesion molecule.
NONE
NONE
NONE
NONE
Organisation of CME activities with Biogen-Idec, EMD Serono, Novartis, TEVANeuroscience, Genzyme.
NONE
Investigator-initiated studies funded by Biogen-Idec, by Novartis,EMD Serono, and by Genzyme.
CIHR grant (co-investigator). MS Society of Canada (co-investigator).
MS Society of Canada.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Catherine Larochelle, MD, PhD (catherine.larochelle.med{at}ssss.gouv.qc.ca),
Sanofi-Genzyme, Actelion, Novartis, Biogen, EMD-Serono
NONE
Sanofi-Genzyme, Novartis, Biogen, EMD-Serono
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Grant for Multiple Sclerosis Innovation from Merck-EMD-Serono
CIHR, FRQ-S
NONE
Multiple Sclerosis Society of Canada
NONE
NONE
NONE
NONE
NONE
NONE
- Alexandre Prat, MD, PhD (a.prat{at}umontreal.ca) and
Biogen, EMD Serono, Teva, Celgene, Sanofi, Roche
NONE
NONE
(1) Multiple Sclerosis Journal, associate editor; (2) Cellular Immunology, associate editor
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
1-CIHR 2-MSSC 3-PMSA
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Expert Opinion to the Federal Court of Canada
- Nathalie Arbour, PhD
NONE
NONE
NONE
Editoral Board for Multiple Sclerosis Journal NO compensation
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Canadian Institutes of Health Research- 2014-2019 and 2020- 2025 Natural Sciences and Engineering Research Council-2019-2024
Research Chair Neurosurgery-Université de Montreal- 2019- 2024
Multiple Sclerosis Society of Canada 2017-2020
NONE
NONE
NONE
NONE
NONE
NONE
- From the Department of Neurosciences (A.C.M., Y.C.S., F.L., N.F-k., A.L., S.E.J.Z., M.G., P.D., C.L., A.P., N.A.), Université de Montréal and Centre de Recherche du CHUM (CRCHUM) Montreal; MS-CHUM Clinic (B.L., M.G., P.D., C.L., A.P.); CLSC des Faubourgs (J.V.G.), CIUSSS du Centre-Sud-de-l’Ile-de-Montréal; and Department of Microbiology, Infectious Diseases, and Immunology and Department of Pediatrics (E.H.), Université de Montréal, Centre de Recherche du Centre Hospitalier Universitaire Sainte-Justine (CHU Sainte-Justine), Montreal, Quebec, Canada.
- Correspondence
Dr. Arbour nathalie.arbour{at}umontreal.ca
Article usage
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Hastening the Diagnosis of Amyotrophic Lateral Sclerosis
Dr. Brian Callaghan and Dr. Kellen Quigg
► Watch
Related Articles
- No related articles found.